1. CCLHD Research

Cecily J Forsyth

View Statistics Email Alert RSS Feed

Profile

Loading... 2 0 20 0 false
Credit Name
Cecily J Forsyth
Full Name
Forsyth, Cecily J
ORCID
Loading... 3 0 20 0 false

Publications

Results 1-20 of 50 (Search time: 0.009 seconds).

Issue DateTitleAuthor(s)
120-Dec-2022Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryNguyen, James; Wellard, Cameron; Chung, Eliza; Cheah, Chan Y; Dickinson, Michael; Doo, Nicole Wong; Keane, Colm; Talaulikar, Dipti; Berkahn, Leanne; Morgan, Susan; Hamad, Nada; Cochrane, Tara; Johnston, Anna M; Forsyth, Cecily J ; Opat, Stephen; Barraclough, Allison; Mutsando, Howard; Ratnasingam, Sumita; Giri, Pratyush; Wood, Erica M; McQuilten, Zoe K; Hawkes, Eliza A
214-Jun-2022Paraprotein associated heparin resistance during cardiopulmonary bypassKhuong, Jacqueline N; Forsyth, Cecily J ; Manuel, Lucy; Kingsford-Smith, Kate; Srivastava, Arpit; Bassin, Levi
3Jul-2021Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: A case reportRogers, James ; Forsyth, Cecily J ; Ford, Tom ; Mikhail, Philopatir 
4Oct-2020Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference ProductForsyth, Cecily J 
5Apr-2020Cutaneous multiple myelomaForsyth, Cecily J ; Jagger, Jacqueline 
6Feb-2020Two monogenic disorders masquerading as one: severe congenital neutropenia with monocytosis and non-syndromic sensorineural hearing lossForsyth, Cecily J 
7Sep-2019Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantationForsyth, Cecily J 
8Apr-2019Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014Forsyth, Cecily J 
9Apr-2019The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemiaForsyth, Cecily J 
10Jan-2019Hereditary haemorrhagic telangiectasiaForsyth, Cecily J ; Mangkorntongsakul, Varitsara 
11Dec-2018The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complicationsForsyth, Cecily J 
12Nov-2018Recommendations for the use of pegylated interferon-alpha in the treatment of classical myeloproliferative neoplasmsForsyth, Cecily J ; Chan, Wai-Hoong 
13Aug-2018Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk FeaturesForsyth, Cecily J 
14Apr-2018Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic LeukaemiaForsyth, Cecily J 
15Jan-2018Delayed-onset heparin-induced thrombocytopenia complicated by arterial and venous thrombosesForsyth, Cecily J ; Harrison
16May-2017Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyForsyth, Cecily J 
17May-2017The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemiaForsyth, Cecily J 
18May-2017Raccoon eyes in systemic light chain amyloidosisForsyth, Cecily J ; Tiley, Campbell 
19Mar-2017A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosisForsyth, Cecily J 
20Feb-2017Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Forsyth, Cecily J